Dannielle Appelhans - Net Worth and Insider Trading

Dannielle Appelhans Net Worth

The estimated net worth of Dannielle Appelhans is at least $70,800 dollars as of 2024-05-15. Dannielle Appelhans is the Director of Generation Bio Co and owns about 20,000 shares of Generation Bio Co (GBIO) stock worth over $70,800. Dannielle Appelhans is also the CEO and President of Rubius Therapeutics Inc and owns about 0 shares of Rubius Therapeutics Inc (RUBY) stock worth over $0. Details can be seen in Dannielle Appelhans's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Dannielle Appelhans has not made any transactions after 2023-12-08 and currently still holds the listed stock(s).

Transaction Summary of Dannielle Appelhans

To

Dannielle Appelhans Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dannielle Appelhans owns 2 companies in total, including Rubius Therapeutics Inc (RUBY) , and Generation Bio Co (GBIO) .

Click here to see the complete history of Dannielle Appelhans’s form 4 insider trades.

Insider Ownership Summary of Dannielle Appelhans

Ticker Comapny Transaction Date Type of Owner
RUBY Rubius Therapeutics Inc 2023-02-24 CEO and President
GBIO Generation Bio Co 2023-12-08 director

Dannielle Appelhans Latest Holdings Summary

Dannielle Appelhans currently owns a total of 2 stocks. Among these stocks, Dannielle Appelhans owns 20,000 shares of Generation Bio Co (GBIO) as of December 8, 2023, with a value of $70,800 and a weighting of 100%. Dannielle Appelhans also owns 0 shares of Rubius Therapeutics Inc (RUBY) as of February 24, 2023, with a value of $0 and a weighting of 0%.

Latest Holdings of Dannielle Appelhans

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GBIO Generation Bio Co 2023-12-08 20,000 3.54 70,800
RUBY Rubius Therapeutics Inc 2023-02-24 0 0.06 0

Holding Weightings of Dannielle Appelhans


Dannielle Appelhans Form 4 Trading Tracker

According to the SEC Form 4 filings, Dannielle Appelhans has made a total of 2 transactions in Generation Bio Co (GBIO) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Generation Bio Co is the acquisition of 8,000 shares on December 8, 2023, which cost Dannielle Appelhans around $14,320.

According to the SEC Form 4 filings, Dannielle Appelhans has made a total of 3 transactions in Rubius Therapeutics Inc (RUBY) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Rubius Therapeutics Inc is the sale of 10,385 shares on February 24, 2023, which brought Dannielle Appelhans around $1,350.

Insider Trading History of Dannielle Appelhans

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dannielle Appelhans Trading Performance

GuruFocus tracks the stock performance after each of Dannielle Appelhans's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dannielle Appelhans is 94.02%. GuruFocus also compares Dannielle Appelhans's trading performance to market benchmark return within the same time period. The performance of stocks bought by Dannielle Appelhans within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Dannielle Appelhans's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Dannielle Appelhans

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 20.23
Relative Return to S&P 500(%) 17.2

Dannielle Appelhans Ownership Network

Ownership Network List of Dannielle Appelhans

No Data

Ownership Network Relation of Dannielle Appelhans


Dannielle Appelhans Owned Company Details

What does Rubius Therapeutics Inc do?

Who are the key executives at Rubius Therapeutics Inc?

Dannielle Appelhans is the CEO and President of Rubius Therapeutics Inc. Other key executives at Rubius Therapeutics Inc include director & Chief Executive Officer Pablo J Cagnoni , Chief Scientific Officer Laurence A. Turka , and CLO & Corp. Secretary Maiken Keson-brookes .

Rubius Therapeutics Inc (RUBY) Insider Trades Summary

Over the past 18 months, Dannielle Appelhans made 2 insider transaction in Rubius Therapeutics Inc (RUBY) with a net sale of 14,263. Other recent insider transactions involving Rubius Therapeutics Inc (RUBY) include a net sale of 15,688 shares made by Pablo J Cagnoni , a net sale of 2,593 shares made by Laurence A. Turka ,

In summary, during the past 3 months, insiders sold 0 shares of Rubius Therapeutics Inc (RUBY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 32,544 shares of Rubius Therapeutics Inc (RUBY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 32,544 shares.

Rubius Therapeutics Inc (RUBY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Rubius Therapeutics Inc Insider Transactions

No Available Data

Dannielle Appelhans Mailing Address

Above is the net worth, insider trading, and ownership report for Dannielle Appelhans. You might contact Dannielle Appelhans via mailing address: C/o Rubius Therapeutics, Inc., 399 Binney Street, Suite 300, Cambridge Ma 02139.

Discussions on Dannielle Appelhans

No discussions yet.